LncRNA MEG3 impacts proliferation, invasion, and migration of ovarian cancer cells through regulating PTEN

被引:69
作者
Wang, Juelan [1 ,2 ]
Xu, Wenqian [3 ]
He, Yangke [1 ,2 ]
Xia, Qi [1 ,2 ]
Liu, Siwei [2 ,4 ]
机构
[1] Sichuan Acad Med Sci, Dept Oncol, Chengdu 610072, Sichuan, Peoples R China
[2] Sichuan Prov Peoples Hosp, 32 West Sect 2,First Ring Rd, Chengdu 610072, Sichuan, Peoples R China
[3] Third Mil Med Univ, Daping Hosp, Dept Cardiol, Chongqing 400042, Peoples R China
[4] Sichuan Acad Med Sci, Dept Obstet & Gynecol, 32 West Sect 2,First Ring Rd, Chengdu 610072, Sichuan, Peoples R China
关键词
Ovarian cancer; LncRNA MEG3; PTEN; LONG NONCODING RNA; TUMOR-SUPPRESSOR; CARCINOMA CELLS; POOR-PROGNOSIS; EXPRESSION; PROMOTES; BREAST; GROWTH; METASTASIS; RESISTANCE;
D O I
10.1007/s00011-018-1186-z
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Objective and designWe investigated the expressions of lncRNA MEG3 and PTEN in ovarian cancer tissues and their effects on cell proliferation, cycle and apoptosis of ovarian cancer.MethodsExpression levels of MEG3 in ovarian cancer cell lines and normal ovarian cell lines were detected by qRT-PCR. Cell viability was detected by MTT assay. Cell apoptosis and cell cycle distribution were measured by flow cytometry. Cell invasion capability was tested by transwell assay. Cell migration capacity was tested by wound healing. The xenograft model was constructed to explore the effect of lncRNA MEG3 on ovarian cancer in vivo.ResultCompared with normal ovarian cells, expression levels of MEG3 and PTEN were relatively lower in ovarian cancer cells. There was a positive correlation between the expression of PTEN and the expression of MEG3. Enhanced expression level of PTEN suppressed SKOV3 cell proliferation, increased cell apoptosis rate, and decreased cell invasion and migration.ConclusionLncRNA MEG3 and PTEN were down-regulated in ovarian cancer cells. LncRNA MEG3 regulated the downstream gene PTEN in ovarian cancer cells to prohibit cell proliferation, promote apoptosis and block cell cycle progression.
引用
收藏
页码:927 / 936
页数:10
相关论文
共 34 条
  • [1] Integrin-linked kinase activity modulates the pro-metastatic behavior of ovarian cancer cells
    Bruney, Lana
    Liu, Yueying
    Grisoli, Anne
    Ravosa, Matthew J.
    Stack, M. Sharon
    [J]. ONCOTARGET, 2016, 7 (16) : 21968 - 21981
  • [2] Cui Ling, 2013, Sichuan Da Xue Xue Bao Yi Xue Ban, V44, P57
  • [3] The multiple roles of PTEN in tumor suppression
    Di Cristofano, A
    Pandolfi, PP
    [J]. CELL, 2000, 100 (04) : 387 - 390
  • [4] MicroRNA-17-5p induces drug resistance and invasion of ovarian carcinoma cells by targeting PTEN signaling
    Fang, Ying
    Xu, Changyan
    Fu, Yan
    [J]. JOURNAL OF BIOLOGICAL RESEARCH-THESSALONIKI, 2015, 22
  • [5] The functional role of long non-coding RNA in human carcinomas
    Gibb, Ewan A.
    Brown, Carolyn J.
    Lam, Wan L.
    [J]. MOLECULAR CANCER, 2011, 10
  • [6] PTEN: tumour suppressor, multifunctional growth regulator and more
    Goberdhan, DCI
    Wilson, C
    [J]. HUMAN MOLECULAR GENETICS, 2003, 12 : R239 - R248
  • [7] Itamochi Hiroaki, 2010, World J Biol Chem, V1, P209, DOI 10.4331/wjbc.v1.i7.209
  • [8] PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
    Li, J
    Yen, C
    Liaw, D
    Podsypanina, K
    Bose, S
    Wang, SI
    Puc, J
    Miliaresis, C
    Rodgers, L
    McCombie, R
    Bigner, SH
    Giovanella, BC
    Ittmann, M
    Tycko, B
    Hibshoosh, H
    Wigler, MH
    Parsons, R
    [J]. SCIENCE, 1997, 275 (5308) : 1943 - 1947
  • [9] Upregulation of MiR-205 transcriptionally suppresses SMAD4 and PTEN and contributes to human ovarian cancer progression
    Li, Juanni
    Hu, Kuan
    Gong, Guanghui
    Zhu, Ding
    Wang, Yixuan
    Liu, Hailing
    Wu, Xiaoying
    [J]. SCIENTIFIC REPORTS, 2017, 7
  • [10] MicroRNA-216a promotes the metastasis and epithelial-mesenchymal transition of ovarian cancer by suppressing the PTEN/AKT pathway
    Liu, Haizhi
    Pan, Ying
    Han, Xiaoxue
    Liu, Jia
    Li, Ruiman
    [J]. ONCOTARGETS AND THERAPY, 2017, 10 : 2701 - 2709